title: The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
abstract: It is clear that cancers comprise a mixture of clones, a feature termed intra-clonal heterogeneity, that compete for spatial and nutritional resources in a fashion that leads to disease progression and therapy resistance. This process of competition resembles the schema proposed by Darwin to explain the origin of the species, and applying these evolutionary biology concepts to cancer has the potential to improve our treatment strategies. Multiple myeloma (MM) has a unique set of characteristics that makes it a perfect model in which to study the presence of intra-clonal heterogeneity and its impact on therapy. Novel therapies have improved the outcome of MM patients, increasing both progression-free and overall survival. Current therapy comprises an induction, consolidation and maintenance phases and it is important to consider how these components of MM therapy are affected by the presence of intra-clonal heterogeneity. In this evolutionary context therapy can be considered as a selective pressure differentially acting on the myeloma clones and impacting on their chances of survival. In this review current knowledge of intra-clonal heterogeneity, as well as its impact on the different components of MM treatment is discussed.
authors.affiliation: Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, UK; Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
authors.forename: Annamaria
authors.initials: A
authors.lastname: Brioli
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Melchor
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Morgan
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D019070:Cell Lineage; D002999:Clone Cells / Q000187:drug effects / Q000473:pathology; D060830:Consolidation Chemotherapy; D004273:DNA, Neoplasm / Q000235:genetics; D019468:Disease Management; D018450:Disease Progression; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D019143:Evolution, Molecular; D006801:Humans; D060046:Maintenance Chemotherapy; D008954:Models, Biological; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D009154:Mutation; D009362:Neoplasm Metastasis; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000473:pathology; D010954:Plasmacytoma / Q000188:drug therapy / Q000473:pathology; D012074:Remission Induction; D012641:Selection, Genetic; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm
keywords: clonal heterogeneity; genetics; multiple myeloma; sequential treatment; therapy